Ligand Pharmaceuticals Incorporated (LGND)
Ligand Pharmaceuticals Incorporated at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Ligand Pharmaceuticals Incorporated (LGND) is a Biotechnology company based in US with a market capitalization of $4.7B. Revenue grew 60.4% year-over-year and the company generated $48.9M in free cash flow. This page tracks LGND's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 68 employees · IPO Nov 18, 1992
Valuation
Valuation & price
$213.21as of May 17, 2026· -32.5% vs 52w high
34.8
P/E ratio
Latest-FY diluted EPS
4.57
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$4.7B
Market cap
60.4%
Revenue growth (YoY)
97.5%
Gross margin
$48.9M
Free cash flow (USD)
-$282M
Net debt
Net cash position
5.7%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $1.63)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 25, 2026Filing
Convertible Notes Issued
- 8-K eventJun 22, 2026Filing
Credit Agreement Amendment
- 8-K eventJun 9, 2026Filing
Annual Meeting Results
- 8-K eventMay 18, 2026Filing
Merger Agreement Amendment
- Quarterly reportMay 8, 2026Filing
10-Q Filed
- 8-K eventMay 7, 2026Filing
Earnings Release
- 8-K eventApr 30, 2026Filing
Program Termination
- 8-K eventApr 27, 2026Filing
Merger Agreement
Questions
Frequently asked questions
What is Ligand Pharmaceuticals Incorporated's market cap?
Ligand Pharmaceuticals Incorporated (LGND) has a market capitalization of $4.7B.
What is LGND's P/E ratio?
LGND trades at a price-to-earnings ratio of 34.8, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is LGND's price-to-book (P/B) ratio?
LGND trades at 4.57 times book value per share.
When did Ligand Pharmaceuticals Incorporated last report earnings?
LGND last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying LGND stock?
SEC Form 4 filings show no open-market insider buys at Ligand Pharmaceuticals Incorporated in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.